COMPANY

Delivering on the Promise 
of Nanomedicine

Nanospectra Biosciences is a medical device company pioneering a patient-centric use of namomedicine for selective thermal ablation. The company is bringing a new technology model to market for tissue ablation that maximizes patient benefits while minimizing side effects. In addition, Nanospectra is leveraging proprietary nanoshell technology for additional clinical applications and strategic partnerships. Based in Houston, Texas, the company was founded on intellectual property from Rice University and collaborative research with scientists at MD Anderson Cancer Center.

MANAGEMENT

David Jorden

David Jorden

CEO and Director

Over 20 years’ executive management and investment experience in the life sciences field.

Glenn P. Goodrich, PhD

Glenn P. Goodrich, PhD

COO & Vice President, Process Development & Chemistry

Extensive experience with fabrication and application of nanoparticles. Trained as a post-doctoral fellow under Dr. Naomi Halas at Rice University.

Jon Schwartz, PhD

Jon Schwartz, PhD

Director, Clinical Research

Primary area of research in the development of minimally-invasive tumor ablation techniques using nanoparticles. Responsible for the conduct of Nanospectra’s clinical studies.

BOARD OF DIRECTORS

Patrick W. Pace, MD

Patrick W. Pace, MD

Chairman of the Board

Owner at PICO LLC. Recently led a recapitalization of the company and a strategic change in focus.

Brad Nyberg

Brad Nyberg

Co-founder of Scarlet Fire Private Investment, LP in Houston, TX. Experience investing and growing development stage companies for successful exits.

David Jorden

David Jorden

CEO and Director

Over 20 years’ executive management and investment experience in the life sciences field.

L. Blair Shamel

L. Blair Shamel

Thirty years’ sales, marketing and commercialization experience in the business of prostate cancer. Launched first commercial assay for PSA. Experience includes Hybritech, Ablation Technologies, DiagnoCure, Metabolon and SNP Bio.

Brian Pryor, PhD

Brian Pryor, PhD

CEO and Co-founder, LiteCure LLC. Developed and commercialized several lasers and light based technologies.

SCIENTIFIC ADVISORS

Naomi Halas, PhD

Naomi Halas, PhD

Co-founder; Professor, Rice University

Inventor of nanoparticles with tunable optical properties, controlled by their shape and structure. Authored over 200 referenced publications. Visit halas.rice.edu for more information.

Jennifer West, PhD

Jennifer West, PhD

Co-founder; Professor, Duke University

Primary area of research in the development of minimally-invasive tumor ablation techniques using nanoparticles.

PARTNERS

Sebacia, Inc is an exclusive licensee of Nanospectra intellectual property for the use of proprietary microparticles in the treatment of moderate to severe acne. With a special coating and silica core, Sebacia microparticles are designed to be activated by the light from commonly used hair removal lasers. When exposed to a laser pulse, they create a focused photothermal effect in the sebaceous gland and follicle to reduce the activity level of the gland and the inflammation that causes acne.

Sebacia Microparticles received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in the second half of 2018.

The product is CE Marked in Europe and sold in select markets.

Nanospectra has an exclusive commercialization partnership with LiteCure, LLC for the use of nanoshells in veterinary medicine, initially for the ablative treatment of solid tumors and surface lesions in dogs and cats. The treatment involves two phases, which mimic the approach in humans. First, the animal is infused with gold nanoparticles that concentrate around blood vessels associated with tumors. Next, a non-ablative laser is used to heat up the nanoparticles that kill the tumor cells without undue damage to the skin or normal tissue. Interest among specialists appears strong based on initial clinical study data presented at the 2017 Annual Conference of the Veterinary Cancer Society.

Commercial launch of the nanoshell treatment is expected in 2019.

INVESTORS

Nanospectra’s proprietary technology, addressing a market trend towards safer, less invasive therapies, has come of age with complementary MRI/ultrasound fusion imaging. The company has moved product into the clinic and demonstrated clinical safety and efficacy in patients. AuroLase Therapy for the ablation of prostate tissue may control the middle ground between active surveillance and radical therapy with its superior safety profile and cost-effective approach compared to surgery, radiation or traditional focal therapies. Further, the technology is extendable into other cancer conditions.

The company’s expertise in nanoparticle manufacturing creates competitive advantages (through barriers to entry at scale with reasonable cost under cGMP). In addition, established and potential exclusive license agreements provide near term royalties and strategic supply revenues.

Nanospectra Biosciences, Inc.

Contact Us

If you would like to send us an email, please use the form below.

8285 El Rio St # 150, Houston, TX 77054

(713) 842-2720 info@nanospectra.com